2014. Huisman EL et al. – Cost-effectiveness and budget impact study of solvent/detergent (SD) treated plasma (octaplasLG®) versus fresh-frozen plasma (FFP) in any patient receiving transfusion in Canada

 

Huisman EL, van Eerd MC, Ouwens JN, de Peuter MA. Cost-effectiveness and budget impact study of solvent/detergent (SD) treated plasma guardian™ versus fresh-frozen plasma (FFP) in any patient receiving transfusion in Canada. Transfus Apher Sci. 2014;51(1):25-34.

https://www.ncbi.nlm.nih.gov/pubmed/23707561

Full article link

Summary

The objectives of this study were to evaluate the cost-effectiveness and budget impact of octaplasLG(®) compared with fresh-frozen plasma (FFP) in all patients receiving a transfusion in Canada. A decision analytic framework was used to model acute and long-term complications that could follow plasma transfusion. Over a life time horizon, the cost with octaplasLG(®) were CA$612.91, which is CA$303.14 less than those with FFP. OctaplasLG(®) resulted in 0.021 quality adjusted life years (QALYs) gained in comparison with FFP. Because of higher efficacy and lower costs, octaplasLG(®) is expected to be the dominant treatment option over FFP in Canada.